eLearningClasses.com

Transgene and Hypertrust Patient Data Care Announce Successful Go-Live of the World’s First Blockchain Solution for Clinical Trials of Personalized Healthcare

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Regulatory News:

Transgene (Paris:TNG) and Hypertrust Patient Data Care today announced as a world premiere the first productive blockchain solution for clinical trials of personalized healthcare, leveraging the Hypertrust X-Chain for Clinical Trials product. The cloud-based solution monitors and orchestrates the supply chain processes of Transgenes AI-enhanced TG4050 individualized therapeutic vaccine based on the myvac technology, against ovarian, head and neck cancer providing an immutable audit trail throughout the treatment process.

The innovative collaboration between Transgene and Hypertrust marks a milestone in the ongoing fight against cancer. The blockchain-based Hypertrust X-Chain solution supports Transgenes personalized immunotherapies comprehensively, ensuring a trustworthy process in the background of the medical treatment. All emerging personalized treatments have a massive need for trustworthy and decentralized solutions, due to the strong cross-company collaborative nature of the production process.

Transgenes first individualized immunotherapy product candidate is based on the myvac technology. It is currently evaluated in two ongoing clinical trials, including patients in Europe and in the USA. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) that are identified and selected using state-of-the-art artificial intelligence capabilities. myvac-based products are designed to stimulate the patients immune response, to recognize and destroy tumor cells based on their own mutations. This individualized immunotherapy is developed specifically for each patient.

We have set up multiple collaborations around the world to allow each patients anticancer therapy to be designed in a timely manner. Blockchain technologies are a perfect tool to ensure that the patients genetic data are protected while ensuring that all the interventions of our partners are both smooth and tracked. We were very happy to collaborate with Hypertrust and together set up this novel process, demonstrating once again Transgenes ability to be at the forefront of innovation, commented Eric Qumneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer of Transgene.

We are very proud to present with our partner Transgene the worlds first productive blockchain solution for clinical trials of personalized healthcare. The combination of Transgenes innovative and AI-enhanced TG4050 cancer vaccine, combined with the security and workflow orchestration features of our platform provides the optimum support for a highly personalized cancer treatment process, says Andreas G¶bel, CEO of Hypertrust Patient Data Care.

Especially in clinical trials of personalized healthcare there is an essential need for an immutable audit trail, which is created by different parties throughout the supply and production process. Blockchain technologies bring a high level of trust, as it allows a total transparency on how the data were modified throughout the process and provide additional protection in an age of increasing cyberthreats.

Hypertrust X-Chain for Clinical Trials by Hypertrust Patient Data Care is a market-leading solution for the orchestration and documentation of clinical trials for personalized healthcare. It ensures the chain of identity and custody for personalized treatments in the context of clinical trials. The decentralized platform leverages blockchain technology, to provide closed-loop supply chain monitoring and orchestration, based on a workflow process definition. The solution provides an immutable and tamper-proof audit trail of all recorded data throughout the treatment. Also, it allows the migration towards the commercial scale solution X-Chain for Commercialized Treatments.

About Transgene

Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgenes programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Companys clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO„¢ platform).

With Transgenes myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO„¢, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO„¢ collaboration with AstraZeneca.

Additional information about Transgene is available at: www.transgene.fr or on Twitter: @TransgeneSA

About myvac

myvac is a viral vector (MVA) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac-derived products are designed to stimulate the patients immune system, recognize and destroy tumors using the patients own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded an Investment for the Future funding from Bpifrance for the development of its platform myvac. TG4050 is the first myvac-derived product being evaluated in clinical trials.

About Hypertrust Patient Data Care

Hypertrust Patient Data Care provides next-generation digital health and supply chain solutions leveraging blockchain, AI and IoT. Hypertrust X-Chain delivers a blockchain-based solution securing a patient-centered closed-loop supply and distributed data chain for autologous cell therapies. Hypertrust X-Chain enables a safe, efficient and transparent workflow orchestration across the entire supply chain of autologous cell therapies “ with far-reaching benefits for pharma companies and all other stakeholders in the supply and data chain. Hypertrust Patient Data Care is a spin-off of CAMELOT Consulting Group.

Hypertrust PR contact:

Nadine Pflaum

Marketing Lead

Hypertrust Patient Data Care GmbH

Radlkoferstr. 2 | 81373 München | Germany

Phone: +49 89 74 11 85-414

Email: [email protected]

www.hypertrust-patient.com

Transgene PR contacts:

Lucie Larguier

Director Corporate Communications & IR

+33 (0)3 88 27 91 04

[email protected]

Citigate Dewe Rogerson (Media)

David Dible/Sylvie Berrebi

+ 44 (0)20 7638 9571

[email protected]